204 related articles for article (PubMed ID: 15914197)
1. Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity.
Goodell V; Disis ML
J Immunol Methods; 2005 Apr; 299(1-2):129-38. PubMed ID: 15914197
[TBL] [Abstract][Full Text] [Related]
2. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
[TBL] [Abstract][Full Text] [Related]
5. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
[TBL] [Abstract][Full Text] [Related]
6. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
Disis ML; Schiffman K; Guthrie K; Salazar LG; Knutson KL; Goodell V; dela Rosa C; Cheever MA
J Clin Oncol; 2004 May; 22(10):1916-25. PubMed ID: 15143085
[TBL] [Abstract][Full Text] [Related]
7. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.
McCabe A; Dolled-Filhart M; Camp RL; Rimm DL
J Natl Cancer Inst; 2005 Dec; 97(24):1808-15. PubMed ID: 16368942
[TBL] [Abstract][Full Text] [Related]
8. CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant protein.
Türeci O; Luxemburger U; Heinen H; Mack U; Sybrecht GW; Huber C; Sahin U
J Immunol Methods; 2004 Jun; 289(1-2):191-9. PubMed ID: 15251424
[TBL] [Abstract][Full Text] [Related]
9. A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer.
Agaylan A; Binder D; Sauer M; Neuweiler H; Meyer O; Kiesewetter H; Salama A
Cancer; 2007 Dec; 110(11):2502-6. PubMed ID: 17932907
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
11. p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP
Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945
[TBL] [Abstract][Full Text] [Related]
12. Clinical translation of peptide-based vaccine trials: the HER-2/neu model.
Disis ML; Knutson KL; McNeel DG; Davis D; Schiffman K
Crit Rev Immunol; 2001; 21(1-3):263-73. PubMed ID: 11642608
[TBL] [Abstract][Full Text] [Related]
13. Rapid and sensitive immunomagnetic-electrochemiluminescent detection of p53 antibodies in human serum.
Yan G; Xing D; Tan S; Chen Q
J Immunol Methods; 2004 May; 288(1-2):47-54. PubMed ID: 15183084
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer.
Yasuda M; Takenoyama M; Obata Y; Sugaya M; So T; Hanagiri T; Sugio K; Yasumoto K
Cancer Res; 2002 Mar; 62(6):1751-6. PubMed ID: 11912150
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.
Zhang JY; Casiano CA; Peng XX; Koziol JA; Chan EK; Tan EM
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):136-43. PubMed ID: 12582023
[TBL] [Abstract][Full Text] [Related]
16. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
17. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity.
Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A
Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies to human melanoma-associated antigens: an amplified enzyme-linked immunosorbent assay for the detection of antigen, antibody, and immune complexes.
Morgan AC; McIntyre RF
Cancer Res; 1983 Jul; 43(7):3155-9. PubMed ID: 6850625
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.
Salazar LG; Coveler AL; Swensen RE; Gooley TA; Goodell V; Schiffman K; Disis ML
Clin Immunol; 2007 Dec; 125(3):275-80. PubMed ID: 17913588
[TBL] [Abstract][Full Text] [Related]
20. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
